Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis

PartnershipYuviwelPositive

AI Analysis

Summary

Biomarin has granted Ascendis a non-exclusive worldwide license to use navepegritide for Yuviwel in achondroplasia, receiving 18-20% royalties on net sales. This represents a significant revenue-sharing arrangement for Biomarin on Ascendis's recently approved drug.

Outcome Details

Non-exclusive worldwide license agreement with 18-20% royalty on net sales

Importance:6/10

Sentiment:

0.60

licensingroyaltiesachondroplasiapartnershippatent settlement

Related Companies

$BMRN $ASND

Read the original article

Published by BioSpace on August 31, 2026 3:06 PM

Read Original